CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.39 USD | -5.57% |
|
-4.24% | -40.84% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 11.74M | Sales 2025 * | 12.57M | Capitalization | 324M |
|---|---|---|---|---|---|
| Net income 2024 * | -167M | Net income 2025 * | -218M | EV / Sales 2024 * | 27.6 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 25.8 x |
| P/E ratio 2024 * |
-1.95
x | P/E ratio 2025 * |
-1.72
x | Employees | 158 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.94% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -5.57% | ||
| 1 week | -7.12% | ||
| Current month | -6.61% | ||
| 1 month | -15.46% | ||
| 3 months | -50.94% | ||
| 6 months | -28.33% | ||
| Current year | -40.84% |
1 week
3.37
3.92
1 month
3.374.21
Current year
3.378.33
1 year
3.378.59
3 years
3.3732.65
5 years
3.3732.65
10 years
3.3732.65
| Managers | Title | Age | Since |
|---|---|---|---|
Rachel Haurwitz
FOU | Founder | 38 | 11-10-27 |
Jason O’Byrne
DFI | Director of Finance/CFO | 54 | 21-02-08 |
Steven Kanner
CTO | Chief Tech/Sci/R&D Officer | 65 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 21-03-31 | |
Scott Braunstein
BRD | Director/Board Member | 60 | 21-05-31 |
| Director/Board Member | 59 | 21-11-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.97% | 2 M€ | -25.75% | ||
| 0.61% | 14 M€ | -3.66% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 3.39 | -5.57% | 2,514,542 |
| 24-05-16 | 3.59 | -1.37% | 1,765,841 |
| 24-05-15 | 3.64 | 0.00% | 2,469,187 |
| 24-05-14 | 3.64 | -1.89% | 1,460,756 |
| 24-05-13 | 3.71 | +4.80% | 2,382,321 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.39
USD
Average target price
19.75
USD
Spread / Average Target
+482.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.84% | 324M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- CRBU Stock